In 2026 the research supply grew and two reviews were sped up
An April 2026 executive order told federal agencies to prioritise psychedelics, the FDA put two psilocybin programmes on its fastest review track, and the research quota rose.
What the study found
Psilocybin's research supply and review speed both moved in 2026
An April 2026 executive order told federal agencies to prioritise psychedelics for serious mental illness, and six days later the FDA put two psilocybin programmes on its fastest review track. A January rule had already raised how much may legally be made for research to 50,000 grams.
The caveat · Faster review is not approval
None of it changes what psilocybin legally is. An executive order can tell agencies to move faster without approving a drug or shifting its legal class. A priority voucher shortens the review clock for two companies' own applications. The quota governs what may be manufactured for research, not what anyone may possess. The state programmes run in tension with federal law rather than replacing it.